[STUDY_ID_REMOVED] 
 
Study ID:  191622-105 
 
Title: BOTOX® Treatment in Pediatric Uppe r Limb Spasticity: Open-label Study 
 
Protocol Amendment 4 Date: [ADDRESS_933009] 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 1  
 Title Page 
ALLERGAN – CONFIDENTIAL 
The following contains confidential, proprietary information  
which is the property of Allergan 
STUDY TITLE 
BOTOX® Treatment in Pediatric Upper Limb Spa sticity:  Open-label Study  
 
Protocol Number:   191622-[ADDRESS_933010] Number: 2012-000043-27 
Phase: [ADDRESS_933011]: BOTOX® (botulinum toxin type A) purified neurotoxin 
complex (US Adopted Name [CONTACT_687984]) 
Sponsor:  Allergan (North America) 
[ADDRESS_933012] Irvine, [LOCATION_004] [LOCATION_003] 
[ZIP_CODE] 
+[PHONE_10421] +[PHONE_10422]  Allergan Ltd. 1st Floor, Marlow International, 
The Parkway, Marlow 
Buckinghamshire SL7 1YL [LOCATION_008] Tel: +44 (0) 1628 494444 Fax: +44 (0) 1628 494449  
   
 
  
   
 
  
 
 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 2  
 Refer to the final 
page of this protocol for electronic 
signature [CONTACT_51472]. 
 
The following information can be found on FDA Form 1572 and/or study contacts page:  
Name [CONTACT_3669] [CONTACT_687966]; name, address, and statement of quali fications of each invest igator; name [CONTACT_687985]; name [CONTACT_287472]; name [CONTACT_160489]; 21 CFR 312.23 
section 6(iii)b. 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 3  
 INVESTIGATOR SIGNATURE [CONTACT_249625]:  
STUDY LOCATION:  
 
I agree to: 
• Implement and conduct this study diligently a nd in strict compliance with the protocol, 
good clinical practices and all ap plicable laws and regulations. 
• Maintain all information supplied by [CONTACT_249595], when this information 
is submitted to an Institutional Review Board (IRB), Independent Ethics Committee 
(IEC) or another group, it will be submitted with a designation that the material is 
confidential. 
 
I have read this protocol in its en tirety and I agree to all aspects. 
     
Investigator Printed Name  [CONTACT_687986] :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 [ADDRESS_933013] of Figures ............................................................................................................... ............ 8  
Protocol Summary .................................................................................................................... 9  
1. Background and Clinical Rationale ................................................................................. 18  
1.1 Pediatric Spasticity ................................................................................................. 18  
1.2 Management of Spasticity in Children ................................................................... 19  
1.3 BOTOX for Management of Pediatric Spasticity .................................................. 20  
1.3.1 Use of BOTOX in Pediatric Lower Limb Spasticity ............................... 21  
1.3.2 Use of BOTOX in Pediatric Upper Limb Pediatric Spasticity ................ 21  
1.4 Dose Justification ................................................................................................... 22  
2. Study Objectives and Clinical Hypotheses ...................................................................... 24  
2.1 Study Objectives .................................................................................................... 24  
2.2 Clinical Hypothesis ................................................................................................ 25  
3. Study Design .................................................................................................................. .. 25 
3.1 Safety Data Review Committee ............................................................................. 28  
4. Study Population and Entry Criteria ................................................................................ 28  
4.1 Number of Patients ................................................................................................. 28  
4.2 Study Population Characteristics ........................................................................... 28  
4.3 Inclusion Criteria .................................................................................................... 29  
4.4 Exclusion Criteria................................................................................................... 31  
4.5 Permissible and Prohibited Medications/Treatments ............................................. 34  
4.5.1 Permissible Medicati ons/Treatments ....................................................... 34  
[IP_ADDRESS] Acceptable Contraceptive Methods and Definition of Females of 
Childbearing Potential ................................................................. 34  
4.5.2 Prohibited Medications/Treatments ......................................................... 35  
4.5.3 Special Diet or Activities ......................................................................... 36  
5. Study Treatments ............................................................................................................. 36 
5.1 Study Treatments and Formulations ....................................................................... 36  
5.2 Methods for Blinding ............................................................................................. 36  
5.3 Method for Assignment to  Treatment Groups ........................................................ 36  
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 5  
 5.4 Treatment Regimen and Dosing ............................................................................. 37  
5.4.1 Treatment Cycle 1 for De Novo Patients ................................................. 37  
5.4.2 Treatment Cycle 1 for Rollover Patients ................................................. 38  
5.4.3 Treatment Cycles 2 Through 5 fo r All Patients (Rollover and De Novo) 38  
5.4.4 Treatment Regimen/Dosage Adjustment ................................................. 40  
[IP_ADDRESS] Retreatment Criteria ..................................................................... 40  
5.4.5 Retreatment Visits ................................................................................... 40  
5.5 Storage of Study Medications/Treatments ............................................................. 41  
5.6 Preparation of Study Medications/Treatments ....................................................... 41  
5.7 Treatment Administration ...................................................................................... 41  
6. Response Measures and Summary of  Data Collection Methods ..................................... 42  
6.1 Efficacy Measures .................................................................................................. 42  
6.1.1 Primary Efficacy Measure ....................................................................... 42  
6.2 Safety Measures ..................................................................................................... 42  
6.3 Examination Procedures, Tests, Equipment, and Techniques ................................ 42  
6.4 Other Study Supplies .............................................................................................. 43  
6.5 Summary of Methods of Data Collection .............................................................. 43  
7. Statistical Procedures ....................................................................................................... 44 
7.1 Analysis Populations .............................................................................................. 44  
7.2 Collection and Derivation of Primary and Secondary Efficacy Assessments ........ 44  
7.2.1 Efficacy Variables .................................................................................... 45  
7.2.2 Primary Efficacy Variable ....................................................................... 45  
7.3 Hypothesis and Methods of Analysis ..................................................................... 45  
7.3.1 Efficacy Analyses .................................................................................... 45  
7.3.2 Safety Analyses ....................................................................................... 46  
7.4 Subgroup Analyses ................................................................................................. 46  
7.5 Sample Size Calculation ........................................................................................ 46  
7.6 Interim Analyses..................................................................................................... 47  
   
   
   
   
   

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 6  
    
   
   
   
   
   
   
   
8.4 Instructions for the Patients .................................................................................... 54  
8.5 Unscheduled Visits ................................................................................................. 55  
8.6 Compliance with Protocol ...................................................................................... 55  
8.7 Early Discontinuation of Patients .......................................................................... 55  
8.8 Withdrawal Criteria ................................................................................................ 55  
8.9 Study Termination .................................................................................................. 56  
9. Adverse Events ................................................................................................................  56 
9.1 Definitions .............................................................................................................. 56  
9.1.1 Adverse Event ......................................................................................... 56  
9.1.2 Serious Adverse Event ............................................................................. 56  
9.1.3 Severity .................................................................................................... 57  
9.1.4 Relationship to Study Drug or Study Procedure ..................................... 57  
9.2 Procedures for Reporting Adverse Events ............................................................. 57  
9.3 Procedures for Reporting a Serious Adverse Event ............................................... 58  
10. Administrative Items ....................................................................................................... 58  
10.1 Protection of Human Subjects ................................................................................ 59  
10.1.1 Compliance with Informed Consent Regulations (US 21 CFR Part 50) 
and Relevant Country Regulations .......................................................... 59  
10.1.2 Compliance With IRB or IEC Regulations ............................................. 59  
10.1.3 Compliance With Good Clinical Practice ............................................... 59  
10.1.4 Compliance With Electronic Records;  Electronic Signatures Regulations 
(US 21 CFR Part 11) ............................................................................... 59  
10.2 Changes to the Protocol ......................................................................................... 59  
10.3 Patient Confidentiality ........................................................................................... 60  
10.3.1 Patient Privacy ......................................................................................... 60  
10.4 Documentation ....................................................................................................... 60  

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 7  
 10.4.1 Source Documents ................................................................................... 60  
10.4.2 Case Report Form Completion ................................................................ 61  
10.4.3 Study Summary ....................................................................................... 62  
10.4.4 Retention of Documentation ................................................................... 62  
10.5 Labeling, Packaging, and Return or Dis posal of Study Medications/Treatments .. 62  
10.5.1 Labeling/Packaging ................................................................................. 62  
10.5.2 Clinical Supply Inventory ....................................................................... 63  
10.5.3 Return or Disposal of Study Medica tions/Treatments and/or Supplies .. 63  
10.6 Monitoring by [CONTACT_1034] .................................................................................... 63  
10.7 Handling of Biological Specimens......................................................................... 63  
10.8 Publications ............................................................................................................ 64  
10.9 Coordinating Investigator ...................................................................................... 64  
11. References .................................................................................................................... .... 64 
12. Attachments ................................................................................................................... .. 69 
 
   
   
   
   
   
   
   
   
   
 
       
12.2 Package Insert/Summary of Product Characteristics ............................................. 81  
12.3 Glossary of Abbreviations ...................................................................................... 82  
12.4 Protocol Amendment 1 Summary .......................................................................... 84  

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 8  
 12.5 Protocol Amendment 2 Summary .......................................................................... 86  
12.6 Protocol Amendment 3 Summary .......................................................................... 91  
12.7 Protocol Amendment 4 Summary .......................................................................... 93  
 
 
   
 
   
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 9  
 Protocol Summary 
 
Study Compound: BOTOX® (botulinum toxin type A) purified neurotoxin complex (US Adopted Name [CONTACT_687987]) 
Phase:  3 
Study Objectives:  To evaluate the long-term safety of repeated doses of BOTOX for the treatment of pediatric 
upper limb spasticity   
Clinical Hypothesis:  Repeated doses of BOTOX (up to 8 U/kg in the upper limb alone and up to 10 U/kg in a 
combination of upper and lower limbs ) have an acceptable safety profile  for treating pediatric upper limb 
spasticity (with or without treatment in the lower limb)   
Study Design 
Structure:  Multicenter, open-label study  
Duration:  Approximately 60 weeks  
Study Treatment Groups :  BOTOX 
Controls:  None 
Dosage/Dose Regimen (BOTOX doses are expressed per body weight) :   
There will be up to [ADDRESS_933014] treatment cycle, de novo patients (who did not participate in Allergan Study 191622-101) are to 
receive at least 6 U/kg and not to exceed 8 U/kg or 30 0 U in the affected upper limb (referred to as the study 
upper limb).  Patients with clinically  significant lower limb spasticity may be eligible to receive BOTOX 
treatment in affected lower limb(s).  The combined upper and lower limb dose should not exceed 8 U/kg or 300 
U, whichever is lower. Rollover patients (who participated in Allergan Study 191622-101 ), during the first trea tment cycle may receive 
up to a maximum of 8 U/kg (not to exceed 300 U) in the same upper limb that was treated in Study 191622-101 
(referred to as the study upper limb).  Patients with clini cally significant lower limb spasticity may be eligible to 
receive BOTOX treatment in affected lower limb(s) up to a maximum of 8 U/kg (not to exceed 300 U).  The 
combined upper and lower limb dose should not exceed 8 U/kg or [ADDRESS_933015] cycle. 
For treatment cycles 2 through 5, the maximum dose for the study upper limb only remains the same as in 
treatment cycle 1; the maximum dose for combined upper and lower limbs or for both lower limbs only for 
triplegic patients can be increased to 10 U/kg (not to exceed 340 U). 
If a patient meets the retreatment criteria, including no  indication of an unacceptable safety risk, and it is 
considered clinically appropriate by [CONTACT_093], the patient should receive at least 6 U/kg in the study 
upper limb every 12 to 14 weeks, with the total dose not to exceed the maximum sp ecified for each treatment 
cycle. 
Randomization/Stratification :   
No randomization or stratification will be  performed for this open-label study. 
   
 
 
 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 [ADDRESS_933016] udy 191622-101  without major protocol devi ations (eg, noncompliance 
to protocol-required procedures) and have not experienced an adverse event that, in the investigator’s opi[INVESTIGATOR_1649], 
may indicate an unacceptable safety risk for additional BOTOX treatments may be eligible for enrollment in 
this study (referred to as rollover patients).  Patients who became pregnant during Study 191622-101 cannot be 
enrolled in this study.  
Additionally, de novo patients (who did not participate in Study 191622-101) who meet the inclusion criteria 
and do not meet the exclusion criteria may be enrolled in this study. Number of Patients :   
Approximately 213 patients will be enrolled. 
Condition/Disease :   
Medically stable monoplegic, hemiplegic, or triplegic pediatric patients with upper limb spasticity involving the 
elbow and/or wrist flexor muscles with single-arm sparing (only 1 arm requiring treatment for spasticity during 
the study) due to cerebral palsy or stroke 
   
 
  
 
 
 
  
  
  
 
  
 
 
 
  
De novo 
patients:  
• Male or female, 2 to 16 years and 11 months of age (prior to 17th birthday) at the day 1 visit 
• Minimum weight of 10 kg at the screening and day 1 visits 
  
 
 
 
  
   
  
 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 11  
   
  
  
 
 
  
 
  
  
  
 
 
  
 
Key Exclusion Criteria  (all patients except where noted otherwise): 
  
• Any 
medical condition that may put the patient at increased risk with exposure to Botulinum Toxin Type A 
Purified Neurotoxin Complex, including diagnosed muscular dystrophy (eg, Duchenne’s muscular 
dystrophy), myasthenia gravis, Ea ton-Lambert syndrome, amyotrophic lateral sclerosis, mitochondrial 
disease, or any other significant disease that might interfere with neuromuscular function  
  
• Uncontrolled epi[INVESTIGATOR_002]  
 
  
 
 
 
  
  
  
 
• Botulinum toxin therapy of any serotype for any conditi on within 3 months prior to the day 1 visit (de novo 
patients only)  
  
 
 
  
• History of surgical intervention of the study upper limb within 12 months prior to the day 1 visit (de novo 
patients only) or planned surgical intervention of any limb(s) during the study 
  

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 12  
   
 
  
 
 
Response Measures 
Safety measures: 
• Adverse events 
   
  
   
  
   
  
   
  
  
  
  
 
  
  
General St
atistical Methods and Types of Analyses:    
Safety data will be analyzed  on the basis of all treated  patients based on treatment  received, defined as the 
safety population.  Efficacy data will be analyzed on the basis of all treat ed patients who have at least 1 MAS-B 
score recorded after day 1. 
Safety variables such as the incidence of adverse events  
 
   
 
 
 
Sample Size Calculation :   
Approximately 213 patients will be enrolled.  The sample size was determined empi[INVESTIGATOR_3675].  

 
 
 
 
Approval  Date:  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 13  
 

 
 
 
Approval  Date:  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 14  
 

 
 
 
Approval  Date:  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 15  
 

 
 
 
Approval  Date:  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 16  
 

 
 
 
Approval  Date:  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 17  
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 18  
  1. Background and Clinical Rationale  
1.1 Pediatric Spasticity 
Spasticity is classically defined as a disorder of the sensorimotor system characterized by a 
velocity-dependent increase in muscle tone  with exaggerated tendon jerks, resulting from 
hyperexcitability of th e stretch reflex (Lance, 1980 ).  The most common cause of focal 
spasticity in children is cere bral palsy.  Cerebral palsy is a disorder caused by a non-
progressive insult of the central nervous system (CNS) that occu rs prenatally, perinatally, or 
during the first 2 years of life and can result in functional motor impairment, irregular 
movement and abnormal posture.  The increase in  the muscle-stretch reflex causes muscle 
contraction of abnormal strength and duration.   Spastic muscles show “velocity-dependent” 
resistance to passive movement and exaggerated tendon jerks (Lance, 1980). 
The patterns of spasticity depend on the areas of the developi[INVESTIGATOR_687954].  In 
patients with hemiplegic spasticity, one half of  the body (1 arm and 1 leg) is affected with 
spasticity.  Approximately 25% of children w ith cerebral palsy present with hemiplegic 
spasticity in which the upper limb is usually more affected than the lower limb 
(Stanley et al, 2000).  Spastic diplegia is characterized by [CONTACT_687967].  Although the arms are less affected, they may still show abnormal 
reflexes and reduced dexterity.  Spastic triplegia is characterized by [CONTACT_687968] [ADDRESS_933017] common form of spastic 
cerebral palsy affecting approxima tely 20% of patients.  Since both cerebral hemispheres are 
affected, intellectual impairment is common.  Patients with quadriplegia may also have 
severe dysarthria, dysphagia and other como rbidities such as epi[INVESTIGATOR_687955].  
Spasticity and abnormal muscle tone contribute both to impairment of function and reduced 
longitudinal muscle growth in children with cerebral palsy ( Dunne et al, 1995 ).   
Cerebral palsy is the most common etiology a ssociated with pediat ric spasticity with a 
prevalence rate of approximately 2.5 in 1000 liv e births, a number that has increased from 
1.5 in 1000 live births 40 years ago ( Odding et al, 2006) and is considered to be the most 
severe childhood physical disability ( Beckung and Hagberg, 2002 ).  Essentially all patients 
with cerebral palsy have impaired motor functi on with spasticity affecting as many as 90%.  
Other less prevalent types of disorders asso ciated with pediatric spasticity include 
posttraumatic brain or spi[INVESTIGATOR_1828], multiple sclerosis, and other neurodegenerative 
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 19  
  conditions ( Hawamdeh et al, 2007 ).  All of these conditions ar e associated with significant 
morbidity and mortality and present an unmet medical need with limited treatment options. 
A less prevalent type of disorder associated with  pediatric spasticity is  stroke.  Information 
on the prevalence of childhood post-stroke spasticity  in the published lite rature is limited.  
The [LOCATION_002] (US) mortality ra te attributable to stroke in children (1 to 5 years of age) is 
0.6 per 100,000.  The case fatality rate for childhood stroke is reported to range from 
7% to 28% ( Lynch et al, 2002).  Based on studies evaluating the effects of stroke by [CONTACT_687969], the rate of motor deficit in pediatric post-stroke  patients ranges from 
40% to about 70% ( Brower et al, 1996 ; De Schryver et al, 2000 ; Keidan et al, 1994 ).  Given 
the low incidence of stroke in children and a ssuming the lowest case-fatality rate (7%) along 
with the worst case scenario of 70% prevalen ce of motor deficits, th e maximum number of 
children with post-stroke spasticity in th e US is estimated to be less than 1500. 
1.[ADDRESS_933018] patients are managed with a 
combination of treatment modalities, includi ng non-pharmacologic, systemic pharmacologic, 
local pharmacologic, and surgical treatments. 
Non-pharmacologic and non-surgical  treatments for spasticity aim to strengthen weakened 
muscles, weaken spastic muscles, and improve joint range of motion as well as motor 
development (Koman et al, 2004 ).  These interventions include occupational therapy (OT), 
physical therapy (PT), orthotics, splints, cas ting and other devices, or any combination of 
these methods.  PT and OT are regarded as e ssential for successful medical and surgical 
interventions (Butler and Darrah, 2001; Dumas et al, 2001 ) but the overall evidence 
supporting this is weak ( Lannin et al, 2006).  A recent study has demonstrated the enhanced 
effectiveness of OT used in combination with BOTOX® (botulinum toxin type A purified 
neurotoxin complex [US Adopted Name, onabot ulinumtoxinA], hereafter referred to as 
BOTOX) ( Wallen et al, 2007). 
Systemic pharmacologic treatments include anti- spastic drugs such as baclofen, dantrolene, 
diazepam, scopolamine, and tizanidine ( Gracies et al, 1997; O’Flaherty and Waugh, 2003; 
Scheinberg et al, 2006; Steinbok, 2006 ).  The aim of systemic pharmacologic management is 
to reduce the muscle overactivity associated with  spasticity.  Mechanisms of action vary but 
the result is either a suppression of muscle excita tion or an enhancement of neural inhibition.  
Response to these medications is variable a nd unpredictable (O’Flaherty and Waugh, 2003).  
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 [ADDRESS_933019] ructures, as well as reduce sensation and cause 
dysesthesias and neuropathic pain ( Gracies et al, 1997).   Intrathecal baclofen is reserved for 
patients with disabling general spasticity th at is unresponsive to conservative 
pharmacotherapy (Koman et al, 2004 ). 
Orthopedic procedures such as contracture release, tendon lengthening, and tendon transfer 
can reduce spasticity symptoms that may result in improved access for hygiene and brace 
(orthotic) tolerability.  These su rgical procedures may also result in pain reduction, as well as 
reduction in bone deformity (osteotomy).  Howe ver, many forms of surgery are best delayed 
until tendons and joints have grown to a reasona ble proportion of their a dult size, since it is 
more difficult to predict the outcome of surg ery in younger children.  Surgical procedures 
have been reported as delayed due to the abil ity of botulinum toxin (type A) therapy to 
minimize fixed muscle shortening and soft tissu e and skeletal deformation associated with 
spasticity ( Molenaers et al, 2006 ). 
Neurosurgical procedures include selectiv e dorsal rhizotomy and selective peripheral 
neurotomy ( Chambers, 1997; Steinbok, 2006).  Selective dorsal rhizotomy is used to treat 
severe spasticity of the lower extremities that in terferes with mobility or positioning.  It is 
usually most effective in a small number of select diplegic or qua driplegic children with 
cerebral palsy who are expected to be independent ambulators.  In children with underlying 
muscle weakness, rhizotomy can worsen rather than improve function. 
1.3 BOTOX for Management of Pediatric Spasticity 
Botulinum neurotoxin type A (BoNT-A) bl ocks neuromuscular conduction by [CONTACT_687970], ente ring the nerve terminals and inhibiting the 
release of acetylcholine.  Wh en injected intramuscularly at therapeutic doses, BoNT-A 
produces localized chemical denervation of the muscle, resulting in focal muscle weakness.  
This muscle weakness is reversible through nerv e ending recovery over a period of 3 or more 
months.  Relaxation of rigid muscles by [CONTACT_322578]-A allows a child to participate in PT or OT, which encourages the use of both targeted and antagonistic muscles wi th goals of muscle 
stretching, strengthening, improved motor contro l, and acquisition of new skills.  There has 
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 [ADDRESS_933020] demonstrated an acceptable safety profile of 
BOTOX at the dose ranges evaluated for this patient population.  Study OCUL-118-8051, a 
placebo-controlled study, included 145 patients (72 BOTOX; 73 placebo) with equinus foot 
deformity who were 2 to 14 years old.  Patient s received injections of BOTOX (4 to 8 U/kg, 
note that BOTOX doses throughout this protocol  are expressed per body weight) or placebo.  
The proportion of responders based on gait pa ttern score was signi ficantly greater (p ≤ 0.05) 
in the BOTOX group compared to the placebo group at weeks 2, 8, and 12.   
Study OCUL-119-8051, an open-label multiple-treatment extension of study 
OCUL-118-8051, included 207 patients who receiv ed injections of BOTOX at 4 U/kg.  For 
the first 2 years of the study the proportion of responders ranged from 39% to 64%.   
Study OCUL-120-8051, a placebo-controlled stud y, included 35 ambulatory patients with 
equinus foot deformity (17 BOTOX; 18 placebo)  who were 2 to 14 years old.  Patients 
randomized to BOTOX received 4 U/kg in the af fected limb.  The proportion of responders 
based on gait pattern score was significantly greater (p ≤ 0.05) in the BOTOX group 
compared to the placebo group at weeks 8 and 12.  Twenty-five of th e 35 patients entered a 
2-year, multiple-treatment open-la bel follow-up study (BTOX-121-8051).   
The fifth study (191622-021), a placebo-controlled study, included 149 patients with equinus 
foot deformity (73 BOTOX; 76 placebo) who were 2 to 8 years old.  Patients randomized to 
BOTOX received 4 U/kg in each affected limb (up to a maximum of 8 U/kg).  No significant 
differences in the proportion of responders ba sed on the gait pattern score were observed 
between the [ADDRESS_933021] of BOTOX in 
children with upper limb spasticity associated with cerebral palsy.  Boyd et al conducted a 
single-center study in Australia, enrolled 30 children (15 pairs with matched age, gender, and 
side of hemiplegia) aged 5 to 15 years (mean  9 years) with hemiplegic cerebral palsy 
(Boyd et al, 2003).  This study was a single treatment study with 3 months follow-up and 
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 22  
  compared training alone to training combined with BOTOX injections.  Doses of 0.5 to 
2.0 U/kg per muscle were injected into selected upper limb muscles with a mean BOTOX 
dose of 4.9 ± 1.6 U/kg (range 3.1 to 8.4 U/kg) .  BOTOX was significantly more effective 
than the control (training alone ) at week 3 (p = 0.002) and at week 12 (p = 0.0001) based on 
the Melbourne Assessment score. 
Koman et al enrolled 50 patients with cerebral palsy ages 3 to 18 years (mean age 9 years) in 
a 26-week double-blind, placebo-controlled study ( Koman et al, 2004a ).  Enrollment 
included patients with hemiplegia (n = 30), dipl egia (n = 7), or quadriplegia (n = 13).  The 
patients were randomized to BOTOX (n = 28) or  placebo (n = 22).  Three injections of 
BOTOX were administered at weeks 0, 8, and 20 at a dose based on the patient’s weight, the 
size of the target muscle(s), and the total numbe r of muscles to be injected.  The mean dose 
of BOTOX was 4.9 U/kg for the first treatment  session, 4.4 U/kg for the second treatment 
session, and 4.6 U/kg for the third treatment session.  The results on the Melbourne 
Assessment showed a significantly improved total score with BOTOX compared to placebo 
at 20 weeks (p = 0.04) and 26 weeks (p < 0.0001). 
Lowe et al conducted a randomized controlled st udy in 42 children with hemiplegic cerebral 
palsy aged 2 to 8 years, (mean 4 years; Lowe et al, 2006).  The study compared the effect of a 
single injection of BOTOX (1 to 2 U/kg per muscle group, maximum total body dose 8 U/kg) 
plus OT to OT alone (control).  The follow-up period was [ADDRESS_933022] (QUEST) but the between-group difference was not significant.  At 
week 4, however, 67% of children treated w ith BOTOX had a clinically significant 20% 
improvement in total QUEST and 71% had a clin ically significant improvement at week 12, 
compared with 19% of control children at week 4 and 33% at week 12 (between-group 
comparisons p = 0.004 and p = 0.03, respectively).  Spasticity, as measured by [CONTACT_336679]-Bohannon (MAS-B) (Bohannon and Smith, 1987 ), was significantly reduced 
in the BOTOX group compared to the control group at weeks 4 and 12. 
The above studies, and additional published studi es, provide evidence of the clinical utility 
and safety of BOTOX in the management of upper and lower limb pediatric spasticity.   
1.4 Dose Justification 
The purpose of this study is to further investigate the safety of BOTOX treatment in pediatric 
cerebral palsy patients wi th upper limb spasticity. 
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 [ADDRESS_933023] muscles could become 
overactive and necessitate the change of dose or the selectio n of muscles to be injected in 
subsequent treatment cycles.   
In clinical practice, the total dose of BOTOX required for management of the impaired limb 
depends on a variety of factors, including goals of treatment as defined by [CONTACT_102]/family 
and physician, number of muscle s to be injected, degree of in creased muscle tone, desired 
degree of muscle relaxation to be achieved, and size/dimensions of the muscle(s).  Allergan 
has consulted with clinical experts in the fi eld of pediatric spastic ity who have recommended 
doses ranging from 3 to 8 U/kg in a single upper limb as doses within this range are likely to 
be efficacious in reducing spasticity and would allow for individualization of the treatment 
paradigm based on individual patient presentation.   
The doses in this study are supported by [CONTACT_687971].  
All of the randomized, controlled studies in upp er limb pediatric spasticity published to date 
utilized total body doses of 8 U/kg or less with the excepti on of 3 studies.  
Wallen et al (2007) and Russo et al ( 2007) evaluated doses up to 13 U/kg (mean 
8.1 ± 2.9 U/kg) and 11.6 U/kg (mean 8.0 ± 2. 2 U/kg), respectively; however, those studies 
included injections to additional upper limb mu scles, such as the shoulder muscles, that do 
not commonly require treatment and are not eligible for injecti on in the present study.  In a 
study conducted by [CONTACT_25715][INVESTIGATOR_687956] ( 2011) doses up to 12 U/kg were used but the dosing details 
are not provided in the publication. The doses in the present study are further s upported by [CONTACT_687972], which are based on many of  the published studies as well as clinical 
experience.  The Cochrane review focused on th e effect of botulinum toxin type A in the 
management of upper limb spasticity in childr en and concluded that doses of BOTOX from 
0.5 to 16 U/kg or up to a total of [ADDRESS_933024] range of upper limb muscles, 
including shoulder muscles for the studies  reporting higher doses, were safe 
(Hoare et al, 2010).  The European consensus paper recently recommended a dose range of 
1 to 20 U/kg with a maximum total dose of 400 U, regardless of location of injection 
(Heinen et al, 2010).  The higher dose ranges were based on studies that allowed injections to 
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 24  
  multiple muscles of varying size in the upper and/or lower limbs ( Heinen et al, 2006; 
Molenaers et al, 2009 ).  Nevertheless, the per-site maximum recommended dose was 50 U, 
which is consistent with the proposed per-site  maximum dose in the present study.  In an 
evidence-based review, the American Academy of Neurology concluded that botulinum toxin 
doses ranging from 2 to 30 U/kg for treatment of the upper and lower limbs are effective and 
generally safe ( Delgado et al, 2010 ).  The upper limb doses from the studies supporting the 
recommendation for upper limb treatment do not exceed the per-muscle maximum doses 
(U/kg) in the current study.  The intern ational consensus stat ement published in 2010 
recommended per-muscle doses ranging from 0. 5 to 4 U/kg with a total dose per treatment 
session not to exceed 16 U/kg or 400 U ( Fehlings et al, 2010 ). 
The doses selected for this study are supporte d by [CONTACT_639226]-observable-a dverse-effect levels 
(NOAELs) established in BOTOX toxicology studies.  In single and repeated-dose studies in 
rats, 10 and 16 U/kg were defined as NOAELs, re spectively.  In monkeys, the single-dose 
intramuscular NOAEL was determined to be  16 U/kg when administered into the 
gastrocnemius muscle.  In repeated-dose toxicity studies in monkeys involving multiple 
injection sites that more closely mimic clinic al use, the NOAEL was 8, 12, or 16 U/kg for 2, 
4, or [ADDRESS_933025] ion of affected muscles 
of the lower limb at doses up to 8 U/kg (not to exceed 300 U) if only the lower limb is 
injected or at doses up to 10 U/kg (not to exceed 340 U) if both upper and lower limbs, or both lower limbs only in triple gic patients, are injected in treatment cycles 2 through 5 to 
optimize individual treatment.  Based on the consensus guidelines, the maximum total body 
dose of 10 U/kg is an acceptable dose for multilevel treatment. 
Based on the above dose considerations, repeated doses of at least 6 U/ kg (maximum 8 U/kg, 
not to exceed 300 U) for the upper limb and up to 8 U/kg (maximum 300 U) for the lower 
limb(s) (not to exceed a maximum total body dose of 10 U/kg or 340 U for upper and lower 
limbs combined or for both lower limbs only in  triplegic patients) are considered to be 
appropriate. 
2. Study Objectives and Clinical Hypotheses  
2.1 Study Objectives 
To evaluate the long-term safety of repeated doses of BOTOX for the treatment of pediatric 
upper limb spasticity.   
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 25  
  2.2 Clinical Hypothesis 
Repeated doses of BOTOX (up to 8 U/kg in the upper limb alone and up to 10 U/kg in a 
combination of upper and lower limbs) have an acceptable safety profile for treating pediatric 
upper limb spasticity (with or without treatment in the lower limb). 
3. Study Design 
This is a multicenter, open-label study eval uating the safety of repeated treatments of 
BOTOX in pediatric upper limb spasticity.  Pa tients who successfully completed Allergan 
Study 191622-101 without major protocol deviations (eg, noncompliance to protocol-
required procedures) may be eligible for enrollm ent in this study (rollover patients) if they 
meet the inclusion criteria and do not meet the exclusion criteria. 
Additionally, de novo patients (who did not particip ate in Allergan Study 191622-101) who 
meet the inclusion criteria and do not meet the exclusion criteria may be enrolled in this 
study.  Depending on the number of rollove r patients from Study 191622-[ADDRESS_933026] to be re -screened for the current 
study; the exit visit from Study 191622-101 becomes the day 1 visit for this study after the 
patient signs the Study 191622-105 informed consent and assent (as applicable).  These visits 
allow up to 5 treatment cycles with  12 weeks between treatments.   
The timing of study visits and treatments is s hown in Figure 1 and Figure 2.  See Section 5.4 
for a detailed description of the treatment regi men and Section 8 for a detailed description of 
the study visits.  For this study, visits base d on day 1 are referred to by “study week” and 
visits based on treatment are referred to by “treatment cycle week.” 
If the patient does not meet the retreatment criteria during the 12-week window, he or she 
may be treated any time up to study week 48 (the  last opportunity for retreatment) but should 
be evaluated at least every 6 weeks (calculated from the latest treatment visit date) until he or 
she meets the retreatment criteri a or until study week 48.  The ex it visit will be study week 48 
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 [ADDRESS_933027] treatment. 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 27  
   

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 28  
  3.1 Safety Data Review Committee  
The safety of the study participants will be monitored by a Safety Data Review Committee 
(SDRC) composed of at least 2 non-Allergan ph ysicians and a study-independent statistician.  
Additional ad hoc participants (eg, physician sp ecialists) may be invited to participate in 
review meetings depending on the safety findings and required scope  of expertise.   
The SDRC will conduct periodic review and a ssessments of the adverse events data 
throughout the entire duration of the study to ensure the safety of the study participants.  The 
SDRC may elect to review additional safety parameters (eg, laboratory data), or change the 
frequency of their review meetings depending upon emerging safety findings or changes in 
patient enrollment rates.   
For additional details regarding SDRC memb ership, standard operational procedures, 
frequency of review meetings, and other details, please refer to the SDRC charter. 
4. Study Population and Entry Criteria 
4.1 Number of Patients  
Approximately 213 patients will be enrolled.   
4.2 Study Population Characteristics 
Medically stable monoplegic, hemiplegic, or triplegic children with upper limb spasticity 
involving the elbow and/or wrist flexor muscles with single-arm sparing due to cerebral palsy 
or stroke are eligible for enrollment in this study. Patients who successfully completed Allergan Study 191622-101 without major protocol 
deviations (eg, noncompliance to protocol-requir ed procedures) and have not experienced an 
adverse event that, in the investigator’s opi[INVESTIGATOR_1649],  may indicate an unacceptable safety risk for 
additional BOTOX treatments may be eligible for enrollment in this study.  Patients who 
became pregnant during Study 191622-101 cannot be enrolled in this study.  
Additionally, de novo patients (who did not participate in Study 191622-101) who meet the 
inclusion criteria and do not meet the exclus ion criteria may be enrolled in this study. 
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 29  
  4.3 Inclusion Criteria 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following are inclusion criteria
 for de novo patients: 
1. Male or female, 2 to 16 years and 11 months of age (prior to 17th birthday) at the day 1 
visit 
2. Minimum weight of 10 kg at th e screening and day 1 visits 
 
 
 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 30  
   
 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 31  
   
 
4.4 Exclusion Criteria 
The following are criteria for exclusion from participating in the study for both rollover 
patients and de novo patients unless otherwise specified: 
 
 
2. Any medical condition that ma
y put the patien t at increased risk with exposure to 
Botulinum Toxin Type A Purified Neurotoxi n Complex, including diagnosed muscular 
dystrophy (eg, Duchenne’s muscular dystr ophy), myasthenia gravis, Eaton-Lambert 
syndrome, amyotrophic lateral sclerosis, mito chondrial disease, or any other significant 
disease that might interfere with neuromuscular function 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 32  
  11. Uncontrolled epi[INVESTIGATOR_002]  
  
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
17. Botulinum toxin therapy of any serotype for any condition within 3 months prior to the 
day 1 visit ( de novo patients only) 
 
 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 [ADDRESS_933028] udy upper limb within 12 months prior to the 
day 1 visit ( de novo patients only) or planned surgical intervention of any limb(s) during 
the study 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 34  
    
  
4.5 Permissible and Prohibited Medications/Treatments 
4.5.1 Permissible Medications/Treatments 
Concomitant anti-spastic medications or muscle  relaxants will be permitted during the study.  
Patients who are already on concomitant anti- spastic medications or muscle relaxants 
(eg, benzodiazepi[INVESTIGATOR_1651], baclofen [oral or pum p], scopolamine [oral or patch], tizanidine, 
vigabatrin, or dantrolene) at the time of the day 1 visit will be encouraged to remain on a 
stable dose and regimen during the study; howev er, dose adjustments to their concomitant 
anti-spastic medications or muscle relaxants will be allowed as clinically indicated.  Initiation 
and adjustment of anti-epi[INVESTIGATOR_687957].  If patient already has an 
intrathecal baclofen pump implanted, intrathe cal baclofen therapy is permitted for both de 
novo and rollover patients during the study at the investigator’s discretion. 
Patients will also be permitted to use soft splints, casts and dynamic splints (UltraFlex®, 
DynaSplint®), and constraint therapy during the study at the investigat or’s discretion. 
However, patients should be asked not to wear the splint for at least 30 minutes before a 
spasticity measure at the office visits. 
Therapy (including OT and PT) considered nece ssary for the patient’s welfare may be given 
at the discretion of the investigator.  If the perm issibility of a specific medication/treatment is 
in question, please contact [CONTACT_78562]. 
[IP_ADDRESS]  Acceptable Contraceptive Method s and Definition of Females 
of Childbearing Potential 
At the time of screening, if a female patie nt is approaching puberty but is not yet of 
childbearing potential, then the patient and/or her legally authorized representative must be 
advised that if she becomes of childbearing potential (defined as females post menarche) 
during the study, she and/or her le gally authorized representative must notify the site of this 
change.  A urine pregnancy test must be perfor med at the patient’s next scheduled visit.  
Upon receiving this notification, the site personnel must advise the patient and/or her legally 
authorized representative of the protocol requirement that any female of childbearing 
potential must use a reliable method of  contraception as described below.   

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 35  
  For females of childbearing potential who may participate in the study, the following 
methods of contraception, if properly used, are generally considered reliable:  oral 
contraceptives, patch contraceptives, injecti on contraceptives, implantable contraceptives, 
male condom with intravaginal spermicide, diaphragm or cervical cap with spermicide, 
vaginal contraceptive ring, intrauterine device, surgical steril ization (bilateral tubal ligation 
or removal of both ovaries), vasectom ized partner, or sexual abstinence. 
The investigator and each patient (and/or her legally authorized representative) will 
determine the appropriate method of contraception for the patien t during their pa rticipation in 
the study.  The method of contraception must be  documented in the patient’s medical record 
and electronic case report forms (eCRFs).  At each study visit, the investigator must counsel 
female patients of childbearing potential and/or their legally authorized representatives 
regarding the importance of main taining their agreed-upon method of contraception.  A urine 
pregnancy test is required prior to each study treatment for female patients of childbearing potential. 
If a female patient of childbearing potential becomes pregnant during the study, the 
investigator will notify Allergan  immediately after the pregnancy is confirmed and the patient 
will be exited from the study after appropriate  safety follow-up.  The investigator will 
(1) notify the patient’s physician that the patient was being treated with BOTOX and 
(2) follow the progress of the pregnancy.  The investigator must document the outcome of the 
pregnancy and provide a copy of the documentation to Allergan. 
4.5.2 Prohibited Medications/Treatments 
Patients should not be permitted to initi ate the following therapy during the study: 
• Anti-spastic medications or muscle rela xants (eg, benzodiazepi[INVESTIGATOR_1651], vigabatrin, 
baclofen [oral or pump], scopolamine [oral or patch], tizanidine, or dantrolene) 
Patients who enter the study on any of the above  concomitant medications should remain on 
a stable dose throughout the study to the extent possible unless j udged by [CONTACT_687973]. 
In addition, the following treatments or  therapy are not permitted during the study: 
• Botulinum toxin therapy of any serotype  (outside of the study treatment)  
• Phenol or alcohol injection to the study upper limb 
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 36  
  • Planned surgery in any limb(s) 
Co-administration of aminoglycosides or other agents that co uld interfere with 
neuromuscular transmission (eg, curare-like agents) s hould only be used with caution as the 
effects of toxin theoretically could be potentiated. 
The decision to administer a prohibited medicati on/treatment is to be done with the safety of 
the patient as the primary consid eration.  Patients may stay in  the study even if a prohibited 
medication is administered.  When possible, Allergan should be notified before the prohibited 
medication/treatment is administered. 
4.5.3 Special Diet or Activities  
OT/PT is an important element of the treatment a pproach in pediatric patients with spasticity.  
While no study-specific OT/PT will be required, patients should follow investigator’s/therapi[INVESTIGATOR_541]’s recommendations re garding appropriate OT/PT.  OT/PT should 
remain consistent, to the extent possible, throughout the entire duration of the study. 
5. Study Treatments  
5.1 Study Treatments and Formulations 
The study treatment will be BOTOX.  BOTOX  contains 100 U 
of Clostridium botulinum toxin type A, 0.5 mg of albumin (human), and 0.9 mg of sodium 
chloride in a sterile, vacuum-dried form wit hout preservative.  The study medication will be 
reconstituted with 2 mL of 0.9% s odium chloride (preservative-free). 
5.2 Methods for Blinding 
This is an open-label study, and therefore no blinding of the study medication is required. 
5.3 Method for Assignment to Treatment Groups 
At the screening visit, after the de novo patient and/or legally aut horized representative has 
signed the informed consent and minor assent (as applicable), the site will call the interactive voice response system (IVRS) or log on to th e interactive web response system (IWRS) to 
obtain the patient number that will serve as  the patient identifi cation number on all study 
documents.  At the study day 1 visit for both de novo and rollover patients, the site will 
access the IVRS/IWRS to enroll the patient.  Ro llover patients transitioning from Allergan 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 37  
  Study 191622-101 will maintain the same patient number that was assigned in that prior 
study.   
Study medication will be labeled with medica tion kit numbers.  At day 1 and at all 
retreatment visits when the patient qualifies fo r retreatment, sites will call the IVRS or log 
onto the IWRS to obtain specific study medicat ion kit numbers for each patient.  Sites will 
dispense study medication according to the IVRS /IWRS instructions.  Sites will receive an 
IVRS/IWRS confirmation notification for each tr ansaction.  All notifications must be 
maintained with the study source documents. 
5.4 Treatment Regimen and Dosing 
Each patient may receive up to 5 treatments during the course of study.  Treatment cycle 1 for 
de novo patients requires identificatio n and injection to the principal muscle group identified 
in the study upper limb.  All other treatments for both rollover and de novo patients allow 
injections to upper limb only, lower limb(s) only,  or a combination of upper and lower limbs.  
If a patient meets the retreatment criteria, in cluding no indication of an unacceptable safety 
risk, and it is considered to be clinically appropriate by [CONTACT_093], the patient should 
receive at least 6 U/kg in the study upper limb ev ery [ADDRESS_933029] 6 U/kg of BOTOX in 
the study upper limb and all muscles in the princi pal muscle group must be injected.  That is, 
if elbow is designated as the principal muscle group, biceps,  brachialis and brachioradialis 
must be injected; if wrist is designated as th e principal muscle group, flexor carpi [INVESTIGATOR_687958]. 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 38  
   
 
  The 
total dose 
injected during this cycle should be no more th an 8 U/kg (not to exceed 300 U) in the upper 
limb only or in a combination of upper and lower limbs. 
5.4.2 Treatment Cycle 1 for Rollover Patients  
Patients transitioning from Study 191622-101 will be  allowed to receive injections in the 
upper limb, the lower limb(s), or a combination of upper and lower limbs in all cycles, 
including treatment cycle 1.   
 
 
5.4.3 Treatment Cycles 2 Through 5 for All Patients (Rollover and 
De Novo)  
For treatment cycles 2 through 5, the maximum dose for treatment only in the study upper 
limb remains the same as for treatment cycle 1; the maximum dose for combined upper and 
lower limbs or for both lower limbs only for tr iplegic patients can be increased to 10 U/kg 
(not to exceed 340 U).  Dose limitations by [CONTACT_687974]:  
• up to 8 U/kg (not to exceed 300 U) for each treatment session if administered only to 
the study upper limb or only to 1 lower limb,  
• up to 10 U/kg (not to exceed 340 U) if ad ministered to a combination of upper and 
lower limbs, or 
• up to 10 U/kg (not to exceed 340 U) if ad ministered to both lower limbs only (for 
triplegic patients only). 
The dose for each muscle and the total dose wi ll be determined by [CONTACT_093].   
 

 
 
 
 
Approval  Date:  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 39  
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 40  
 5.4.4 Treatment Regimen/Dosage Adjustment 
For all patients enrolled, the dose should be calculated based on patient’s body weight in 
kilograms measured on the day of each treatmen t/retreatment visit.  For purposes of dose 
calculation only, the patient’s weight will be ro unded to the nearest whole kilogram.  If the 
dose by [CONTACT_18694] (U/kg x body weight) exceeds the per-muscle dose, the total maximum 
dose for the study upper limb or for the lower li mb(s), or the total body maximum units, then 
the maximum dose (“not to exceed” units) should be used.  The dose for each injection site 
should not exceed 50 U. 
[IP_ADDRESS]  Retreatment Criteria  
Patients may be retreated if they meet all of the following criteria on the day of retreatment 
prior to the injection:   
a.  
 
b. At least [ADDRESS_933030] study treatment of BOTOX 
c. Did not experience the following since previous treatment: 
• adverse events of compromised respi[INVESTIGATOR_4806], aspi[INVESTIGATOR_51520], difficulty 
swallowing, or clinically significant exce ssive salivation.  Patients who have 
experienced these adverse events must not receive any further study treatments. 
• an adverse event or excessive weakness that, based on the investigator’s clinical 
judgment, indicates an unacceptable safety risk for additional BOTOX treatments.  
Patients may be re-evaluated for retreatment once the adverse event or muscle 
weakness is resolved.   
•  
 
 
d. A negative urine pregnancy test for fema le patients of childbearing potential 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 41  
 5.5 Storage of Study Medications/Treatments 
The study medication must be stored in a secu re area and administered only to patients 
entered into the clinical study, at no cost to the patients, in accordance with the conditions 
specified in this protocol. 
 
 
 
 
5.6 Preparation of Study Medications/Treatments 
BOTOX (100 U vial) will be reconstituted with 2 mL of preservative-free saline.   
5.7 Treatment Administration 
Muscle localization techniques such as e-stimulation, sonography, and/or electromyography 
(EMG) are recommended for this study.  Th e study medication may be administered in 
conjunction with appropriate anesthesia accordin g to each investigator’s standard practice.  
Patients who are planning to undergo general anes thesia should be carefully examined by [CONTACT_687975]. 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 42  
 6. Response Measures and Summary  of Data Collection Methods 
6.1 Efficacy Measures 
  
  
  
 
  
 
  
  
6.1.1 Primary Efficacy Measure 
No primary efficacy measure is identified. 
6.2 Safety Measures 
• Adverse events 
   
   
  
  
  
  
 
6.3 Examination Procedures, Tests,  Equipment, and Techniques  
The procedures are described in Attachment 12.1.   

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 43  
 6.4 Other Study Supplies 
The following study supplies will be provided by [CONTACT_687976]: 
• Laboratory kits for the collection and ship ment of hematology, biochemistry, and 
urine samples (including pregnancy kits) will be provided by a vendor (eg, central laboratory) contracted by [CONTACT_78562]  
• Calibrated temperature recorder for m onitoring refrigerator temperatures  
• Syringe labels 
• Goniometer 
• Kilogram-only weight scale for selected sites (weight should  be measured and 
collected in kilograms only) 
The study sites will be responsible for pr oviding the following supplies/equipment : 
• Needles and syringes for study drug reconstitution and injection 
• Sterile saline (0.9% without preservative) for study drug reconstitution 
• Surgical gloves for study drug reconstitution 
•  
 
• Access to a computer with internet c onnection (high-speed connection for eCRF 
completion)  
• Standard 12-lead ECG 
• Weight scale with height meas ure (if not supplied by [CONTACT_78562]) 
• Centrifuge for processing lab samples 
• Ultrasound and/or e-stimulation or EMG device for muscle localization techniques, if 
applicable 
6.5 Summary of Methods of Data Collection 
An IVRS/IWRS will be used to assign patient numbers for de novo patients and to manage 
study medication inventory.  Data will be coll ected using eCRFs via a validated electronic 
data capture system (EDC).  Source documents w ill be used and stored at the sites, and may 
include a patient’s medical records, hospi[INVESTIGATOR_452095], clinical charts, pati ent chart, copy of the 
EDC file, as well as the results  of diagnostic tests such as laboratory tests, ultrasounds, 
x-rays, and ECGs.  A central laboratory will be used for the analysis of all blood samples.  

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 44  
 For patients ≥ 6 years of age at day 1, the C-SSRS w ill be conducted as a clinical interview 
and the scores will be collected from the designated site staff using an electronic data 
collection method (eg, electronic tablet). 
7. Statistical Procedures 
The database lock will occur when all patients have completed the study.  A detailed analysis 
plan will be generated prior to the database lock.  All planned analyses will be performed 
after the database is locked. 
7.[ADDRESS_933031] injection in 
this study will be derived.   

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 [ADDRESS_933032] ing unless otherwise specified. 
  
 
 
 
 
 
 
   
 
 
 
 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 46  
  
7.3.2 Safety Analyses 
Safety variables including the incidence of adverse events,  
 
 
 
 
  
The incidence of 
adverse events will be ta bulated by [CONTACT_687977].   
 
 
 
 
 
 
 
 
   
 
7.4 Subgroup Analyses 
The analyses of adverse events will be presen ted by [CONTACT_687978], 
type of anesthesia, and age group, if appropriate. 
7.5 Sample Size Calculation 
Approximately 213 patients will be enrolled.  The sample size was determined empi[INVESTIGATOR_687959]. 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 47  
 7.6 Interim Analyses 
Periodic safety summaries will be provided to the SDRC for review.  In addition, periodic 
safety and efficacy data summaries may be ge nerated for the purpose of study monitoring.  
An interim safety analysis may be perf ormed for regulatory filing, if needed. 
  
 
 
  
   
  
 
 
  
 
 
 
 
 
 
   
 
 
   
   
 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 48  
  
 
   
   
 
 
 
 
   
 
  
  
  
 
 
 
 
 
  
 
  
  
  
 
 
  
 
 
 
   

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 49  
   
 
 
  
  
  
  
  
 
 
 
 
 
  
  
 
 
 
 
   
  
  
  
  
   
  
 
 
  
  
 
 
 
  
   

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 50  
   
  
   
  
 
  
  
  
  
  
 
  
  
  
  
 
  
   
 
 
    
  
  
 
 
  
 
  
  
  
  
 
.  

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 51  
   
 
   
 
 
  
 
 
  
 
   
  
 
 
 
 
   
  
 
  
 
  
 
 
  
  
  
  
 
   
  
  
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 52  
   
 
  
  
 
  
  
   
  
 
   
  
  
  
  
 
  
  
  
 
 
  
  
  
 
 
   
  
  
 
  
  
   
  
.  

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 53  
    
  
 
  
  
 
  
  
   
  
 
  
 
    
  
  
  
  
 
 
 
  
   
  
 
  
 
 
  

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 54  
   
 
 
  
  
 
  
 
   
   
  
  
  
  
  
 
 
  
  
   
  
 
  
 
  
  
  
 
  
8.4 Instructions for the Patients 
Patients/caregivers will be instructed to stric tly follow the study visit schedule and report any 
changes in condition to the investigative site.   

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 55  
 8.5 Unscheduled Visits 
Unscheduled visits can be performed at the di scretion of the investigator, eg, for safety 
concerns or for retreatment evaluation (if at leas t [ADDRESS_933033] study treatment).  If 
the patient is eligible and receives study trea tment, this visit becomes a treatment visit.  
Additional examinations may be performed as n ecessary to ensure the safety and well being 
of patients during the study.  eCRFs will be completed for each unscheduled visit.   
8.6 Compliance with Protocol 
At each postbaseline visit, patients/caregivers will be questioned on concomitant medication 
use and procedures or test since the last visit to ensure protocol compliance.   
8.[ADDRESS_933034] visit for the patient will be considered  the study exit visit.  Procedures identified in 
Table 1 and Table 2 for the exit/early terminati on visit will be performe d if the study exit visit 
occurs earlier than study week 48.   
8.8 Withdrawal Criteria 
Patients will be withdrawn from the study if they: 
• develop a medically significant hypersensiti vity reaction to the study drug such as 
angioedema or anaphylaxis, or 
• become pregnant during the study 
Patients will continue to be followed up for safe ty until the issue is resolved or the condition 
is stabilized.  Please see Section [IP_ADDRESS] fo r follow-up for patients who become pregnant 
during the study. 
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 [ADDRESS_933035] the right to withdraw a patient from the study at any time 
for any reason.  Patients who withdraw from the study will not be replaced.  
8.9 Study Termination 
The study may be stopped at his/he r study site at any time by [CONTACT_535394].  Allergan 
may stop the study (and/or the study site) for a ny reason with appropriate notification.  
9. Adverse Events  
Adverse events occurring during the study will be recorded on an adverse event eCRF.  If adverse events occur, the first concern will be the safety of the study participants.  
9.[ADDRESS_933036] a causal 
relationship with this treatment.  An advers e event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), sympto m, or disease temporally 
associated with the use of a medicinal (investigational) product, whether or not related to the 
medicinal (investigational) product.  In additi on, during the screening period, adverse events 
will be assessed regardless of the administration of a pharmaceutical product.   
Adverse events will be assessed and documented, as appropriate, throughout the study (ie, 
after informed consent has been obtained).  At each visit, the investigator will begin by 
[CONTACT_687979] t/caregiver a general, non-directed question 
such as “How have you been feeling since the last visit?”  Directed questioning and examination will then be done as appropriate.  All reported adverse events will be 
documented on the appropriate eCRF.   
9.1.2 Serious Adverse Event 
A serious adverse event is any adverse event oc curring at any dose that results in any of the 
following outcomes:  death, a life-threatening adverse event, inpatient hospi[INVESTIGATOR_249589], a persistent or signifi cant disability/in capacity, or a 
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 57  
 congenital anomaly/birth defect.  Important medi cal events that may not result in death, be 
life-threatening, or require hospi[INVESTIGATOR_3767] a serious adverse event when, 
based upon appropriate medical judgment, they may jeopardize the patient or subject and 
may require medical or surgical intervention to  prevent one of the outcomes listed in this 
definition.  (See Section 9.3 for procedur es for reporting a serious adverse event.) 
Note:  Allergan considers all cancer adverse even ts as serious adverse events.  In addition, 
Allergan considers any abortion (spontaneous or nonspontaneous) as a serious adverse event. 
9.1.[ADDRESS_933037] be  completed using the following definitions as 
guidelines: 
Mild Awareness of sign or symptom, but easily tolerated 
Moderate Discomfort enough to cause interference with usual activity 
Severe Incapacitating with inability to work or do usual activity Not applicable In some cases, an advers e event may be an ‘all or nothing’ finding 
which cannot be graded 
 
9.1.4 Relationship to Study Drug or Study Procedure 
A determination will be made of the relations hip (if any) between an adverse event and the 
study drug or study procedure, as applicable.  A causal relationship is present if a 
determination is made that there is a reasonable possibility that the adverse event may have 
been caused by [CONTACT_335851].   
9.[ADDRESS_933038] be recorded on the appropriate eCRF. 
All adverse events that are drug- related and unexpected (not listed as treatment-related in the 
current Investigator’s Brochure) must be re ported to the governing IRB/IEC as required by 
[CONTACT_1201]/IEC, local regulations, and the governing health authorities.  Any adverse event that 
is marked “ongoing” at the exit visit must be followed-up as appropriate. 
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 58  
 9.3 Procedures for Reporting a Serious Adverse Event 
Any serious adverse event occurring during the study period (beginning with informed 
consent) and for at least [ADDRESS_933039] supply Allergan and the IRB/IEC with any additional requested in formation (eg, autopsy reports and terminal 
medical reports).  
In the event of a serious advers e event, the investigator must: 
1. Notify Allergan immediately by [CONTACT_687980] 
(contact [CONTACT_249620] 1 of  the serious adverse event form); phone 
numbers and relevant Allergan personnel c ontacts are also on the front page of 
protocol. 
2. Obtain and maintain in his/her files all pe rtinent medical records, information, and 
medical judgments from colleagues who assist ed in the treatment and follow-up of the 
patient. 
3. Provide Allergan with a complete, written case history (adverse event report form) 
which includes a statement as to whether the event was or was not related to the use of 
the investigational drug. 
4. Promptly inform the governing IRB/IEC of the serious adverse event as required by 
[CONTACT_1201]/IEC, local regulations, and the governing health authorities. 
10. Administrative Items 
This protocol is to be conducted in accord ance with the applicable  Good Clinical Practice 
(GCP) regulations and guidelines, eg, the In ternational Conference on Harmonisation (ICH) 
Guideline on GCP. 
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 59  
 10.1 Protection of Human Subjects 
10.1.1  Compliance with Informed Co nsent Regulations (US 21 CFR 
Part 50) and Relevant Country Regulations 
Written informed consent is to be obtained from  each patient prior to enrollment into the 
study, and/or from the patient’s legally authorized representative.  If the patient is under the 
legal age of consent, the consen t form must be signed by [CONTACT_687981].  
Written parental/legally authorized representative  informed consent in addition to a separate 
written minor consent and/or assent (in acco rdance with any applicable state and local 
laws/regulations) are required for each minor study patient prior to study enrollment or any 
study-related procedures in the study. 
10.1.2  Compliance With IRB or IEC Regulations 
This study is to be conducted in accordance with IRB regulations (US 21 CFR Part 56.103) 
or applicable IEC regulations.  The inves tigator must obtain a pproval from a properly 
constituted IRB/IEC prior to init iating the study and re-approval or review at least annually.  
Allergan is to be notified immediately if the re sponsible IRB/IEC has been  disqualified or if 
proceedings leading to disqualification have begun.  Copi[INVESTIGATOR_28078]/IEC correspondence 
with the investigator should be provided to Allergan. 
10.1.[ADDRESS_933040] ance with the applicable GCP regulations and 
guidelines.  
10.1.4  Compliance With Electronic Reco rds; Electronic Signatures 
Regulations (US 21 CFR Part 11) 
This study is to be conducted in compliance with the regulations on electronic records and 
electronic signature. 
10.[ADDRESS_933041] not implement any devia tion from or changes of the protocol without 
approval by [CONTACT_535398]/favorable opi[INVESTIGATOR_687960] :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 60  
 IRB/IEC of a protocol amendment, except wher e necessary to eliminate immediate hazards 
to study patients, or when the changes involve on ly logistical or admini strative aspects of the 
study (eg, change in monitors, change of telephone numbers). 
10.3 Patient Confidentiality 
A report of the results of this study may be published or sent to the appropriate health 
authorities in any country in which the study drug may ultimately be marketed, but the 
patient’s name [CONTACT_249626].  The patient’s name [CONTACT_249627], Allerg an, or the governing hea lth authorities or the 
FDA if they inspect the study records.  Appr opriate precautions will be taken to maintain 
confidentiality of medical reco rds and personal information. 
10.3.1  Patient Privacy 
Written authorization (US sites only), data protection consent (European sites only), and 
other documentation in accordance with the rele vant country and local privacy requirements 
(where applicable) is to be obtained from each patient prior to enrollment into the study, and/or from the patient’s legally authorized representative in accordan ce with the applicable 
privacy requirements (eg, the Health Insurance Port ability and Accountab ility Act Standards 
for Privacy of Individually Iden tifiable Health Information (“HIPAA”), European Union Data 
Protection Directive 95/46/ EC [“EU Directive”]). 
In accordance with HIPAA requirements, additional purposes of this study include the 
following:   
• to publish anonymous patient data from the study; and 
• to create and maintain a data repository 
10.4 Documentation 
10.4.1  Source Documents 
Source documents may include a pa tient’s medical records, hospi[INVESTIGATOR_1332], clinic charts, the 
investigator’s patient study file s, as well as the results of di agnostic tests such as X-rays, 
laboratory tests, and electrocar diograms.  The investigator’s copy of the case report forms 
serves as part of the investigator’s reco rd of a patient’s study-related data.   
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 61  
 The following information should be entere d into the patient’s medical record: 
• Patient’s name 
• Patient’s contact [CONTACT_3031] 
• The date that the patient entered the study , patient number, and medication kit number 
• The study title and/or the prot ocol number of the study and the name [CONTACT_502190] 
• A statement that informed consent and/ or assent, if applicable was obtained 
(including the date).  A statement that wr itten authorization (US sites only), data 
protection consent (EU sites on ly), or other country and lo cal subject privacy required 
documentation for this study has been  obtained (including the date). 
• A statement that patient meets all the inclus ion criteria and does not meet any of the 
exclusion criteria.  If a patient does not qualify for the study, a screen failure reason 
should be noted. 
• Dates of all patient visits 
• Medical and surgical history  
• Documentation of results of all procedures  conducted during the course of the trial 
including the dose determination process and reason(s) why patient did not meet 
retreatment criteria.  
 
• The results of laboratory tests performed by [CONTACT_3433] e site (eg, results of hematology, serum 
chemistry, HbA1c, and urine pregnancy tests) 
• All concurrent medications (list all pr escription, non-pres cription and herbal 
medications being taken 3 months prior to or at the time of enrollment).  At each 
subsequent visit, changes to  the list of medications and concurrent procedures should 
be recorded. 
• Occurrence and status of  any adverse events 
• The date the patient exited the study, a nd a notation as to whether the patient 
completed the study or reason for discontinuation 
10.4.2  Case Report Form Completion 
The investigator is responsible for ensuring that  data are properly recorded in each patient's 
eCRF and related documents.  An investigator who has signed the protocol signature [CONTACT_687988] (as indicated in the eCRF) to ensure that the 
observations and findings are recorded in the eCRFs correctly and completely.  The eCRFs 
are to be completed in a timely manner. 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 62  
 10.4.3  Study Summary 
An investigator’s summary will be provided to Allergan within a short time after the 
completion of the study, or as designated by [CONTACT_287447].  A summary is also to be provided to 
the responsible IRB/IEC. 
10.4.[ADDRESS_933042].  These documents 
should be retained for a longer period, however , if required by [CONTACT_941] a pplicable re gulatory 
requirement(s) or if needed by [CONTACT_78562]. 
In addition, for countries not falling within th e scope of the ICH guidelines, local regulatory 
requirements should be followed regarding the re tention of clinical study documentation. 
Allergan requires that it be notified in writi ng if the investigator wishes to relinquish 
ownership of the data so that mutually agreed-u pon arrangements can be made for transfer of 
ownership to a suitably qua lified, responsible person. 
10.5 Labeling, Packaging, and Return or Disposal of Study 
Medications/Treatments 
  
  
 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 [ADDRESS_933043] 
supervision of an investigator. 
10.5.3  Return or Disposal of Study Medications/Treatments and/or 
Supplies 
All clinical study medications/treatments and/or  supplies will be returned to Allergan or 
Allergan designee for destruction. 
10.[ADDRESS_933044] 
on-site visits to review, audit and copy study- related documents.  These representatives will 
meet with the investigator(s) and appropriate staff at mutua lly convenient times to discuss 
study-related data and questions. 
10.7 Handling of Biological Specimens 
Laboratory specimens for blood chemistry pa nel, and hematology will be sent to a 
centralized clinical la boratory with certification from a recognized accreditation agency 
(eg, College of American Pathology [C AP] or Clinical Laboratory Improvement 
Amendments [CLIA] certification)  to be assayed using valida ted methods.  Allergan shall 
have full ownership rights to any biological specimens/samples derived from the study.   
Approximately 7 mL of blood is estimated to be co llected at a given visit.  Please refer to the 
Laboratory Manual for details re garding specimen sample collection, processing, storage, 
and shippi[INVESTIGATOR_4585].   
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 [ADDRESS_933045] joint cooperation betw een multiple investig ators and sites and 
Allergan personnel.  Authorship will be establis hed prior to the writing of the manuscript.  As 
this study involves multiple centers, no individu al publications will be allowed prior to 
completion of the final report of the multicente r study except as agreed with Allergan.   
10.9 Coordinating Investigator 
A signatory Coordinating Investigator [INVESTIGATOR_535354]. 
11. References  
Barry MJ, Van Swearingen JM, Albright AL.  Reliability and responsiveness of the Barry-
Albright Dystonia scale.  Dev Med Child Neurol. 1999;41:404-411. 
Beckung E, Hagberg G.  Neuroimpairment, activity limitations, and partic ipation restrictions 
in children with cerebral palsy.  Dev Med Child Neurol. 2002;44:309-316. 
Bohannon RW, Smith MB.  Interrater reliability of a modified  Ashworth scale of muscle 
spasticity. Phys Ther. 1987;67:206-207. 
Boyd R, Bach T, Morris M, Graham HK, Im ms C, Johnson L, et al.  A single blind 
randomized trial of botulinum toxin A (B TX-A) and upper limb training in congenital 
hemiplegia – activity, participation, and heal th-related quality of life.  Dev Med Child 
Neurol. 2003;45(Suppl 96): 10-[ADDRESS_933046] C:3. 
Brower MC, Rollins N, Roach ES.  Basal ganglia and thalamic infarction in children.  Arch 
Neurol. 1996;53:1252-1256. Butler C, Darrah J.  Effects of neurodevelopmen tal treatment (NDT) for cerebral palsy:  an 
AADPDM evidence report.  Dev Me d Child Neurol. 2001;43:778-790. 
Chambers HG.  The surgical treatment of spas ticity.  Muscle Nerve Suppl. 1997;6:S121-128. 
Delgado MR, Hirtz D, Aisen M, Ashwal S, Fe hlings DL, McLaughlin J, et al.  Practice 
parameter:  pharmacologic treatment of spasticity in children and adolescents with cerebral 
palsy (an evidence-based review ).  Neurology. 2010;74:336-343. 
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 65  
 De Schryver ELLM, Kappelle LJ, Jennekens-Schinke l A, Peters ACB.  Prognosis of ischemic 
stroke in childhood: a long-term follow-up st udy.  Dev Med Child Neurol. 2000;42:313-318. 
Dumas HM, O’Neil ME, Fragala MA.  Expert consensus on physical therapi[INVESTIGATOR_687961] A injection for children with cerebral palsy.  Pediatr Phys Ther. 
2001;13:122-132. 
Dunne JW, Heye N, Dunne SL.  Treatment of chr onic limb spasticity with botulinum toxin A.  
J Neurol Neuros Psy. 1995;58:232-235. Eliasson A-C, Krumlinde-Sundholm L, Rosblad B, Beckung E, Arner M, Ohrvall A-M, et al.  
The Manual Ability Classification System (MACS) for children with cerebral palsy: scale 
development and evidence of validity and reliability.  Dev Med Child Neurol. 
2006;48:549-554. 
Fehlings D, Novak I, Berweck S, Hoare B, Stott NS, Russo RN.  Botulinum toxin 
assessment, intervention and follow-up for paedia tric upper limb hyperton icity: international 
consensus statement.  Eur J Neurol. 2010;17(Suppl. 2):38–56. 
Gracies JM, Elovic E, McGuire J, Simpson D.  Traditional pharmacological treatments for 
spasticity.  Part 1:  Local treatmen ts.  Muscle Nerve Suppl. 1997;7:S61-S91. 
Hawamdeh ZM, Ibrahim AI, Al-Qudah AA.  Long- term effect of botulinum toxin (A) in the 
management of calf spasticity in children with diplegic cerebral palsy.  Eura Medicophys. 
2007;43:311-318. 
Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I, van Campenhout A, et al.  
The updated European Consensus 2009 on the use of botulinum toxin for children with 
cerebral palsy.  Eur J Paediatr Neurol. 2010;14:45-66. 
Heinen F, Schroeder AS, Fietzek U, Berweck S.   When it comes to botulinum toxin, children 
and adults are not the same: multimuscle op tion for children with cerebral palsy.  Mov 
Disord. 2006;21:2029-2030. 
Hoare BJ, Wallen MA, Imms C, Villanueva E, Ra wicki HB, Carey L.  Botulinum toxin A as 
an adjunct to treatment in the management of the upper limb in children  with spastic cerebral 
palsy (UPDATE).  Cochrane Database Syst Rev. 2010;(1):CD003469. 
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 66  
 Jethwa A, Jonathan M, Macarthur C, Knights S, Fehlings T, Fehlings D.  Development of the 
Hypertonia Assessment Tool (HAT): a discrimi native tool for hypertonia in children.  Dev 
Med Child Neurol. 2010;52:e83-e87.  
Keidan I, Shahar E, Barzilay Z, Passwell J, Br and N.  Predictors of outcome of stroke in 
infants and children based on clinical data and radiologic correlates.  Acta Paediatr. 
1994;83:762-765. 
Koman IA, Smith BP, Evans P, Williams R, Ri chardson R, Rushing J.  Placebo-controlled, 
double-blind, randomized clinical trial evaluati ng the effect of botulinum toxin A on upper 
extremity spasticity associated with cerebral palsy.  Dev Med Child Neurol. 
2004a;46(Suppl 9):[ADDRESS_933047]-C:3. 
Koman IA, Smith BP, Shilt JS.  Cerebral palsy.  Lancet. 2004;363:1619-1631.   
Lance JW.  Symposium synopsis.  In:  Feldmann RG, Young RR, Koella WP, eds.  Spasticity 
disordered motor control.  Chicago, Illinoi s:  Year Book Medical Publishers; 1980:485-494. 
Lannin N, Scheinberg A, Clark K.  AACPDM systematic review of the effectiveness of 
therapy for children with cerebral palsy after botulinum toxin A injections.  Dev Med Child 
Neurol. 2006;48:533-539. 
Love SC, Valentine JP, Blair EM, Price CJ, Cole  JH, Chauvel PJ.  The effect of botulinum 
toxin type A on the functional ability of the child with spastic hemiplegia: a randomized 
controlled trial.  Eur J Neurol. 2001;8(Suppl 5):50-58. 
Lowe K, Novak I, Cusick A.  Low-dose/high-concentration localized botulinum toxin A 
improves upper limb movement and function in children with hemipleg ic cerebral palsy.  
Dev Med Child Neurol. 2006;48:170-175. 
Lynch JK, Hirtz DG, DeVeber G, Nelson KB .  Report of the National Institute of 
Neurological Disorders and Stroke Workshop on Perinatal and Childhood Stroke.  Pediatrics. 
2002;109:116-123. 
Molenaers G, Desloovere K, Fabry G, de Cock P.  The effects of quan titative gait assessment 
and botulinum toxin A on musculoskeletal surgery in children with cerebral palsy.  J Bone 
Joint Surg. 2006;88:161-170. 
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 [ADDRESS_933048] K, Van Camp enhout A, De Cat J, Pauwels P, et al.  
Long-term use of botulinum toxin type A in  children with cerebral palsy: treatment 
consistency.  Eur J Paediatr Neurol. 2009;13:421-429. 
Odding E, Roebroeck ME, Stam HJ.  The ep idemiology of cerebral palsy: incidence, 
impairments and risk factors.  Disabil Rehabil. 2006;28:183-191. O’Flaherty S, Waugh MC.  Pharmacologic management of the spastic and dystonic upper 
limb in children with cerebral palsy.  Hand Clin. 2003;19:585-589. 
Palisano R, Rosenbaum P, Bartlett D, Livings ton M.  GMFCS – E&R: Gross motor function 
classification system expanded and revised.  2007. Available from: 
http://motorgrowth.canchild.ca/en/GMFCS/resources/GMFCS-ER.pdf. 
Pi[INVESTIGATOR_77091] K, Herceg M, Wick F, Grim-Stieger M, Bernert G, Paternostro-Sluga T.  Functional 
electrical stimulation combined with botuli num toxin type A to improve hand function in 
children with spastic hemiparesis - a pi[INVESTIGATOR_799].  Wien Klin Wochenschr. 2011;123:100-105. 
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al.  The 
Columbia- Suicide Severity Rating Scale (C-SSRS) :  Initial validity and internal consistency 
findings from three multi-site studies with adolescents and adults.  Am J Psychiatry.  2011;168:1266-1277. 
Russo RN, Crotty M, Miller MD, Murchland S, Flett P, Haan E.  Upper-limb botulinum toxin 
A injection and occupational therapy in children  with hemiplegic cerebral palsy identified 
from a population register: a single-blind, randomized, controlled trial.  Pediatrics. 
2007;119:e1149-e1158. 
Scheinberg A, Hall K, Lam LT, O’Flaherty S.  Or al baclofen in children with cerebral palsy:  
A double-blind cross-over pi[INVESTIGATOR_799].  J Paediatr Child Health. 2006;42:715-720. 
Stanley F, Blair E, Alberman E.  Cerebral Pa lsy: epi[INVESTIGATOR_687962].  Clinics 
in Developmental Medicine, No 151. London,  England: Mac Keith Press; 2000:4-21. 
Steinbok P.  Selection of treatm ent modalities in children with  spastic cerebral palsy.  
Neurosurg Focus. 2006;21:1-8. von Baeyer CL, Spagrud LJ.  Systematic review  of observational (behavioral) measures of 
pain for children and adolescents aged 3 to 18 years.  Pain. 2007;127:140-150.  
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 68  
 Wallen M, Waugh M-C, O’Flaherty S.  Func tional outcomes of intramuscular botulinum 
toxin type A and occupational therapy in the upp er limbs of children with cerebral palsy:  
a randomized controlled trial.  Arch Phys Med Rehab. 2007;88:1-10. 
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 69  
 12. Attachments  
  
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
   
 
 
 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 70  
  
 
 
 
 
     
  
  
   
   
  
     
   
 
 
 
 
 
   
    
  
 
 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 71  
    

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 72  
   
 
 
 
 
 
  
 
 
 
    
 
 
  
  
 
 
  
  
 
  
 
  
 
  
 
 
  
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 73  
   
 
 
 
 
 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 74  
  

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 75  
   
 
 
 
 
 
 
  
  
 
  
  
  
 
 
 
 
 
  
 
 
 
 
 
   

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 76  
  
   
  
  
  
   
 
 
 
 
 
 
 
  
 
 
 
 
 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 77  
   
  
 
 
  
 
 
 
 
  
  
 
 
  
 
 
 
   
 
 
 
 
 
 
 
 
  
 
 
   
 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 78  
  
 
 
  
 
 
   
 
 
 
 
 
 
 
  
 
  
  
  
  
  
  
  
  
  
  
 
 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 79  
  
 
  
   
   
  
 
  
  
 
  
 
  
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 80  
  
 
 
 
 
  
 
  
 
  
 
 
 
 
 
 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 81  
 12.2 Package Insert/Summary of Product Characteristics 
The appropriate package insert or Summary of Product Characteristics will be supplied to 
investigators in countries where the product is marketed. 
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 82  
 12.3 Glossary of Abbreviations 
Term/Abbreviation Definition 
   
BoNT-A botulinum neurotoxin type A 
BOTOX® botulinum toxin type A purifie d neurotoxin complex (US Adopted 
Name, onabotulinumtoxinA) 
CFR Code of Federal Regulations (US) 
  
CNS central nervous system 
  
D day 
ECG electrocardiogram 
eCRF electronic case report form 
EDC electronic data capture 
EMG electromyography 
EU European Union 
   
GCP Good Clinic al Practices 
  
 
   
HbA1c glycosylated hemoglobin 
HIPAA Health Insurance Portability and Accountability Act Standards for 
Privacy of Individually Identifiable Health Information 
ICH International Conference on Harmonisation 
IEC Independent Ethics Committee 
IRB Institutional Review Board 
IVRS interactive voice response system 
IWRS interactive web response system 
MACS Manual Ability Classification System 
  
   
NA not applicable 
No. number 
NOAEL No-observable-adverse-effect level 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 [ADDRESS_933049] 
  
 
  
 
Scrn screening 
SDRC Safety Data Review Committee 
Tx treatment 
U unit, corresponding to the median lethal dose (LD 50) in mice 
US [LOCATION_002] 
V1 slow velocity 
V3 fast velocity 
Wk week 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 84  
 12.4 Protocol Amendment 1 Summary 
Title:  BOTOX® Treatment in Pediatric Upper Limb Spasticity:  Open-label Study 
Protocol 191622-105, Amendment 1 
Date of Amendment:  30 March 2012 
Amendment Summary 
This summary includes changes made to Protocol 191622-105 (02 December 2011) to 
provide clarifications, updated in formation, and corrections.   
Following is a summary of content-oriented changes that were made to each section of the protocol, and a brief rationale for these change s.  Minor editorial a nd document formatting 
revisions have not been summarized. 
Section(s) Revision Rationale 
Title page Added EudraCT number and 
changed Allergan Medical Safety 
Physician.  Updated information 
 
 
 
 
  
  
 
8.3.1, 
 
  
 
 
  
10.7, 
Handling of 
Biological 
Specimens Revised approximate volume of 
blood collection for hematology 
and chemistry from 5 to 7 mL.  Based on the revised central laboratory 
(Covance) requirements. 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 85  
 Section(s) Revision Rationale 
 
 
   
 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 86  
 12.5 Protocol Amendment 2 Summary 
Title:  BOTOX® Treatment in Pediatric Upper Limb Spasticity:  Open-label Study 
Protocol 191622-105, Amendment 2 
Date of Amendment:  7 December 2012 
Amendment Summary 
This summary includes changes made to Protocol 191622-105 Amendment 1 (e-signature 
[CONTACT_568] 02 April 2012) to provide clarifications and corrections.   
Following is a summary of content-oriented changes that were made to each section of the 
protocol, and a brief rationale for these changes.  Underlining is used to identify wording that 
has been added and strikethrough for wording th at has been deleted.  Minor editorial and 
document formatting revisions have not been summarized. 
Section(s) Revision Rationale 
Summary Changes corresponding to those 
identified below in the body were 
made to the Summary section. For consistency within the protocol 
  
 
 
  
1.4, Dose Justification  5.4, Treatment Regimen and Dosing Table 3 Added wording for a combination of only both lower limbs for triplegic patients  Allows a dose up to 10 U/kg and not to exceed 340 U to be injected during treatment cycles 2 to 5 when only both lower limbs are treated. 
3, Study Design Replaced details regarding dosing 
with a cross reference to Section 5.4, Treatment Regimen and Dosing To consolidate dosing information in a clearly designated section. 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 87  
 Section(s) Revision Rationale 
4.4, Exclusion Criteria Cha nged #21 regarding history of 
fracture in the study upper limb 
within 12 months from “prior to the screening visit” to “prior to the day 1 visit.” For consistency with other criteria 
4.5.2, Prohibited Medications/Treatments Added to the wording that requires a patient to remain on a stable dose of anti-spastic medications: to the 
extent possible unless judged by [CONTACT_687982].  For clarification 
5.3, Method for Assignment to Treatment Groups Added At the study day 1 visit for 
both de novo and rollover, the site 
will access the IVRS/IWRS to 
enroll the patient; For clarification 
5.4, Treatment Regimen and Dosing At the beginning of 5.4, replaced similar wording that was in 5.4.2 and 5.4.3 with:  If a patient meets 
the retreatment criteria, including 
no indication of an unacceptable 
safety risk, and it is considered to 
be clinically appropriate by [CONTACT_1275], the patient should 
receive at least 6 U/kg in the study 
upper limb every 12 to 14 weeks, 
with the total dose not to exceed the 
maximum specified for each 
treatment cycle.  For clarification 
5.4.3, Treatment Cycles 2 Through 5 for All Patients (Rollover and De Novo) Revised description of dose limitations  For clarification 
 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 88  
 Section(s) Revision Rationale 
  
 
 
  
5.4.4, Treatment 
Regimen/Dosage Adjustment Added For purposes of dose 
calculation, the patient’s weight 
will be rounded to the nearest 
whole kilogram.   For clarification 
[IP_ADDRESS], Retreatment Criteria 
 Revised to “Patients should may be 
retreated” if they meet the 
retreatment criteria. For clarification 
5.4.5, Retreatment Visits Deleted sentence regarding dose 
(because that is specified in Section 5.4.3).  Revised the last sentence to “…determine if the patient will be eligible for retreatment and if the above-mentioned dosing regimens are clinically appropriate for the patient 
or dose reduction relative to the last 
injection received is required. For clarification 
6.4, Other Study Supplies For the calibrated temperature 
recorder, deleted mention of freezer temperatures. Only refrigerator monitors are needed and will be supplied. 
 In addition to ultrasound and/or 
e-stimulation, added EMG device for muscle localization, if applicable For clarification 
 
  
  

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 89  
 Section(s) Revision Rationale 
 
 
  
 
    
  
  
 
 
 
  
 
 
 
 
 
 
  
 
 
 
  
 
  
   
 
  
  
    
8.8, Withdrawal Criteria 
 Added that patients will be 
withdrawn from the study if they develop a medically significant hypersensitivity reaction to the study drug such as angioedema or anaphylaxis, or if a patient becomes pregnant during the study. For clarification 
  
 
  
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 90  
 Section(s) Revision Rationale 
  
  
 
 
   

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 91  
 12.6 Protocol Amendment 3 Summary 
Title:  BOTOX® Treatment in Pediatric Upper Limb Spasticity:  Open-label Study 
Protocol 191622-105, Amendment 3 
Date of Amendment:  January 2014 
Amendment Summary 
This summary includes changes made to Protocol 191622-105 Amendment 2 (e-signature 
[CONTACT_568] 11 December 2012).   
 
 
Following is a summary of content-oriented changes that were made to each section of the protocol, and a brief rationale for these change s.  Minor editorial a nd document formatting 
revisions have not been summarized. 
Section(s) Revision Rationale 
Title page Referred to the Study Contacts Page for 
emergency telephone numbers; updated page 2 Per new Allergan protocol 
template 
 
 
 
  
  
 
 
  
 
 
3.1 Changed “mem b
ers” to “participants” and 
removed “or investigator” from the examples 
given of ad hoc SDRC participants Clarification 
 
  
  
 
Protocol Summary; 
4.4 Modified Exclusion Criterion 11a regarding seizure frequency for exclusion Clarification 
 Modified Exclusion Criterion 12 regarding vulnerable respi[INVESTIGATOR_687963] 27 to exclude 
patients with significant suicidality from 
treatment To avoid confounding the 
safety data 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 92  
 Section(s) Revision Rationale 
 
    
 
4.5.1 Added a sentence on use of anti-epi[INVESTIGATOR_687964]-
epi[INVESTIGATOR_687965] 
[IP_ADDRESS] Amended bullet (c) of the retreatment criteria To specify that patients who 
experience certain adverse 
events will not receive 
further study treatments 
5.4.5 Revised paragraph regarding retreatment for 
patients with adverse events of compromised 
respi[INVESTIGATOR_4806], aspi[INVESTIGATOR_1516], difficulty 
swallowing, or clinically significant excessive 
salivation  To specify that patients who 
experience these adverse 
events will not receive 
further study treatments 
6.4 Added bullet that Allergan will supply a 
kilogram-only weight scale for selected sites, 
and that the site will supply it only if it is not 
already supplied by [CONTACT_687983]’s 
weight is collected in 
kilograms only 
   
  
    
  
  
9.[ADDRESS_933050] be 
measured in kilograms  
12.1.2  Added “temporal, rectal” to body temperature As per common practices 
 
 
  
 
12.1.13; 12.1.14 Amended “investigator” to “physician 
investigator” Clarification 
 

 
 
Approval Date :  
 01-Aug-2016Allergan Confidential Protocol 191622-105 Amendment 4 
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex  
 
 93  
 12.7 Protocol Amendment 4 Summary 
Title:  BOTOX® Treatment in Pediatric Upper Limb Spasticity:  Double-blind Study 
Protocol 191622-105, Amendment 4 
Date of Amendment:  July 2016 
Amendment Summary 
This summary includes changes made to Protocol 191622-105 Amendment 3 (January 2014).  
This protocol was amended to decrease the sample size. 
Following is a summary of content-oriented changes that were made to each section of the 
protocol, and a brief rationale for these change s.  Minor editorial a nd document formatting 
revisions have not been summarized. 
Section(s) Revision Rationale 
Title page Updated Allergan medical safety physician 
and Allergan signatory information Change in staff 
Protocol Summary, 
4.1 (Number of Patients) Estimated number of patients to enroll in 
study was decreased from 350 to 213 Based on decreased number 
of completers from DBPC 
study due to adjusted 
treatment differences from 
upper limb studies. 
Protocol Summary; 
7.5 (sample size 
calculation) Number of patients was revised from 350 to 
213.  Based on decreased number 
of completers from DBPC 
study 
 